Back to mobile site

Mizuho stays Outperform on Axsome Therapeutics (AXSM) as Auvelity Rx growth accelerates

March 20, 2026 11:06 AM EDT Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $230.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst commented, "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login